MONROVIA, Calif., April 28, 2011 /PRNewswire/ — STAAR Surgical
Company (NASDAQ:
STAA), a leading developer, manufacturer and marketer of
minimally invasive ophthalmic products, today announced CE Mark
approval for its nanoFLEX™ Collamer® Single Piece IOL
which can be injected through a 2.2 mm incision with the
nanoPOINT™ Injector System. The nanoFLEX IOL
incorporates the Company’s proprietary aspheric optic design
(patent pending), which is optimized for the naturally curved
anatomy of the eye. CE Mark approval allows the Company to
market nanoFLEX in the European Economic Area (EEA) and can serve
as a foundation for some additional approvals in countries outside
the EEA.
Collamer is a highly compressible, unique lens material composed
of collagen, a UV-absorbing chromophore, and a poly-HEMA based
copolymer. The compressibility of the material allows the
lens to be delivered through a small incision in a controlled and
predictable manner. The Collamer material provides excellent
quality of vision due in part to its anti-reflective surface, which
reduces or eliminates the occurrence of glare and halos. In
addition, the Collamer material has demonstrated that it induces
fewer higher order aberrations than other lens materials. It
has a water content of 40% which is over 50% higher than any other
FDA approved hydrophilic IOL material. This same material is
used to manufacture the Company’s worldwide leading refractive
lens, the Visian® ICL™.
“The nanoFLEX approval to market in Europe is a very important
milestone for STAAR Surgical,” said STAAR Surgical CEO Barry G.
Caldwell. “The CE Mark approval positions us to build our
global IOL strategy to drive premium product sales growth in key
and profitable markets throughout the world. The global platform of
our current IOL products includes the current silicone
‘/>”/>
SOURCE